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Abstract
Human infection with Mycobacterium tuberculosis exists as a spectrum of conditions ranging from asymptomatic
infection to active disease. Novel, accurate tuberculosis immunodiagnostics have been introduced over the last
decade, but it remains challenging to timely diagnose active disease and to accurately distinguish asymptomatic
M. tuberculosis infection from immune memory resulting from a prior infection eradicated by the host response.
The conference titled Immunodiagnosis of Tuberculosis: New Questions, New Tools, which was held on September
21-23, 2008 in Virginia Beach, Virginia, United States, brought together basic scientists and clinical experts to dis-
cuss recent progress in tuberculosis research and diagnosis. Global analyses of M. tuberculosis biology and the host
immune response, with emphasis on systems approaches to the study of host-pathogen interactions, were pre-
sented. Moreover, conference participants discussed new tests in the pipeline and reviewed new technologies
leading to novel assay formats. The discussion included technologies ranging from simple, inexpensive point-of-
care tests to automated molecular platforms for detection of multiple infections based on the “lab on a chip” con-
cept. It was also recognized that the utility of any new diagnostic relies on laboratory capacity, accessibility, costs,
and test deployment. The conference included lessons from the field. For example, the application of existing tech-
nologies to neglected areas, such as diagnosis in children and HIV
+ populations, was discussed.
Introduction
The first international meeting on new biomarkers and
tools for the immunodiagnosis of M. tuberculosis infec-
tion and disease, entitled Immunodiagnosis of Tuberculo-
sis: New Questions, New Tools, was held September 21
to 23, 2008 in Virginia Beach, Virginia, United States.
T h eo b j e c t i v eo ft h ec o n f e r e n c ew a st oi n t e g r a t et h e
most recent knowledge generated through basic, transla-
tional, and clinical research that could lead to novel,
improved immunodiagnostic tools for tuberculosis (TB).
About 150 researchers from academia and the private
sector attended the seminar from over 26 countries,
including many developing nations. The agenda
included 20 scientific presentations and a keynote
address by the director of the Stop TB Department at
the World Health Organization (WHO).
TB is still a major killer: one person dies from this
infectious disease every 15 seconds, somewhere in the
world. The interaction between the human host and the
causative agent of TB, the intracellular pathogen Myco-
bacterium tuberculosis, is characterized by the ability of
t h eh o s ti m m u n er e s p o n s et oc o n t r o li n f e c t i o nw i t h o u t
causing sterilization and of the pathogen to withstand
expression of host immunity by changing its metabolic
and growth state. The result is an asymptomatic,
chronic (latent) infection that may last for the lifetime
of the host. In 5-10% of immunocompetent, infected
individuals the host immune response loses control of
infection at some time in the life of the individual:
tubercle bacilli resume growth, and tuberculosis (TB)
develops. Diseased individuals are usually infectious
some time during disease. Their timely identification is
critical to the success of chemotherapy and to curb-
ing transmission of infection. Consequently, the
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a major problem for TB control, as it means that new
disease foci can arise outside of identified at-risk
populations.
Until recently, century-old, often inaccurate methods
have been the mainstay of diagnosis of active disease
and latent infection [1]. Recent effort has resulted in
new immunologic tests for latent infection, while diag-
nosis of active disease typically relies on detecting tuber-
cle bacilli or their products in the patient’s escreate
(sputum). Neither old nor new tests, however, can pre-
dict progression from latent infection to active disease, a
crucial stage for treatment and infection control. The
need for better diagnostics for TB has been strongly
advocated by The Global Plan to Stop TB 2006-2015
(http://www.stoptb.org/global/plan), which calls for uni-
versal access to high-quality diagnosis and research
towards new diagnostics. Moreover, academia, industry,
governmental agencies, and private agencies have
expressed a renewed interest in TB diagnosis. However,
achieving new, accurate TB diagnostics faces formidable
challenges that are both scientific and operational. Over-
coming them requires effective multi-disciplinary com-
munication and collaboration within the scientific
community.
The international conference “Immunodiagnosis of
Tuberculosis: New Questions, New Tools” was planned as
an authoritative venue for establishing partnerships and
consortia leading to the next generation of TB immuno-
diagnostics. The speaker roster was of world-class qual-
ity, and the unique combination of themes concerning
basic and translational research, field studies, and novel
technologies was designed to achieve the conference
goals. With its structure of plenary sessions and poster
sessions, the meeting encouraged discussion and fos-
tered collaboration among scientists in basic research,
translational research, field studies, and industry to link
research on biomarker discovery to a deeper under-
standing of the biology of the pathogen, the immune
response of the host, and the host-pathogen interactions
leading to the expression of immunological markers spe-
cific for various stages of infection (latent infection, pro-
gression, and disease). Moreover, the conference aimed
at establishing links between basic and translational
research (i) by discussing how new markers of infection
and disease identified by basic research could be evalu-
ated in field studies and (ii) by reviewing cutting-edge
technologies that could lead to a new generation of
immunodiagnostic tests. The goals of the conference
were accomplished by integrating (i) discussion of the
biological events associated with expression of immune
markers of recent infection, latent chronic infection,
progression, and active disease, (ii) the identification of
translational research opportunities, (iii) the presentation
of potential innovative new assay formats, and (iv) the
definition of challenges at the preclinical and clinical
stages of test development. Particular attention was
given to pediatric TB, which poses unique diagnostic
challenges, since children typically present a different
disease spectrum than adults and are likely express
immune markers differently from adults due to the
immaturity of the child’s immune response.
Summary of oral presentations during the
plenary sessions
Keynote address: Tuberculosis is a global health issue
Mario Raviglione, director of the World Health Organi-
zation’s (WHO) Stop TB program, opened the confer-
ence with WHO’s perspective on the global TB
situation, discussing the status of the epidemic, progress
that has been made toward eliminating this disease as a
major public health problem worldwide by 2050, and
the critical and urgent need to increase funding for
research to achieve this goal. [2] Raviglione emphasized
that a ten-year funding gap for global TB research and
development has been a major impediment to scientific
progress. A “TB Research Movement” has been con-
ceived to accelerate progress, the goal of which is to sti-
mulate investments, support efforts, accelerate
implementation, and expand the existing portfolio
across the research continuum to ensure development
of tools that will be conducive to global elimination of
TB by 2050. [2] Its objectives are 1) to provide leader-
ship and advocacy to mobilize increased resources in
support of a coherent and comprehensive global TB
research agenda, and 2) to provide a forum for funders
and implementers of TB research to coordinate plans
and actions, with the result of ensuring that research
needs are addressed, opportunities prioritized, and gaps
filled. [2]
Basic TB biology: current knowledge, bottlenecks and
challenges
The meeting began with a review of basic TB biology
that focused on current bottlenecks and challenges in
basic research. Douglas Young opened the session with
a discussion of the biology of latent TB, which he
argued is essential to understanding the fundamental
biology of TB. He specifically addressed current knowl-
edge about why M. tuberculosis is able to resist the
host’s ability to eradicate it over a long period of time.
[3] The commonly-used definition of latent TB—anti-
gen-specific T-cell response without clinical symptoms
—is very broad and, Young argued, may in fact lead us
away from the consideration that latent TB may not act
the same way in every patient. [3] Young also discussed
key scientific questions including whether everyone
infected with latent TB harbors viable bacteria, and if
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what they are doing. [3]
Markus Wenk then discussed the cell biology of intra-
cellular pathogens that has characterized the importance
of lipids at various stages in host-pathogen interactions.
[4] Lipids appear to be “gatekeepers” in important che-
mical reactions involving cell signaling during pathogen
docking, invasion, and movement in and out of cells.
Lipids may be viable targets for regulation of the host-
pathogen interaction. [4]
Sebastien Gagnuex discussed evolutionary forces that
have shaped the genetic diversity in M. tuberculosis,i n
particular natural selection, host migration, and changes
in host demography. [5] JohnJoe McFadden then dis-
cussed the value of system approaches to uncover char-
acteristics of the TB bacillus grown in vivo that could
ultimately be useful as targets for new immunodiagnos-
tic approaches. This approach, he argued, requires an in
silico model of linked metabolic pathways to identify
genes and phenotypes and predict their interactions. [6]
Lastly, Steven Elledge presented a functional genomics
approach to viral-host interactions with HIV. New
screening methodologies developed over the past five
years, based on the novel understanding of the biology
of double-stranded DNA and RNA interference, he
argued, now provide scientists with the tools to carry
out genetic screens of mammalian cells to identify host
functions involved in the interaction with a particular
pathogen. [7]
Basic TB immunology: current knowledge, bottlenecks
and challenges
The second portion of the conference focused on the
host side of TB, covering challenges in TB immunology.
Stefan Kauffman presented research related to using the
metabolic profile of the host response to TB as a basis
for the rational design of vaccines and biomarkers. [8]
Mark Doherty spoke about the potential for identifying
biomarkers of infection, citing examples that indicated
how they could be useful in separating latent and acute
TB. [9] Padmini Salgame posed the question of how hel-
minth infections, which are endemic in areas most
affected by TB, affect progression to active TB or re-
activation of latent TB. She discussed her work with the
Th1/Th2 paradigm to further examine this relationship.
Maria Gennaro spoke about how high-throughput meth-
ods have facilitated the study of antibody responses on
the genome-scale, and she discussed implications of this
technology for monitoring disease progression using ser-
ology and profiling the biology of the tubercle bacilli in
the human host. [10] Muireann Coen discussed the
potential of translating metabolomics discoveries into
tools for diagnosis and systems monitoring, and new
technologies in biomarker discovery. [11]
Pediatric tuberculosis
Joseph Bellanti introduced the differences in the pediatric
immune system that make children more likely to
develop severe TB, and he cited the need for obtaining
new knowledge about the relationship between immune
maturation and developmental immune deficiencies asso-
ciated with infection. [12] Anneke Hesseling then spoke
about pediatric TB from a clinical epidemiological per-
spective, based on her studies in a highly endemic setting
in South Africa. She emphasized the need for improved
diagnostics, improved programs to prevent TB and
TB/HIV co-infection, and shorter treatment regimens
that target children. [13]
Field studies/clinical trials: present and future
Richard Menzies critically analyzed the methods used to
evaluate the effectiveness of new diagnostic tests in the
field, and he outlined a standardized approach that
should be used to provide the necessary evidence of
safety and efficacy. [14] Sandra Arend discussed the
properties of a tuberculosis-specific skin test that
showed promise in preliminary studies as a safe diagnos-
tic that produced a readable skin test response and did
not easily sensitize. [15] Peter Andersen discussed the
value of IGRA-based diagnosis of infection and predic-
tion of active disease, particularly in asymptomatically
infected people. [16]
New technologies: diagnostic assays for resource-rich and
resource-limited settings
Mark Perkins discussed the potential and limitations of
seroimmunodiagnosis for case detection in the context
of global disease care and control, including the need
for either sensitivity or specificity in order for seroim-
munodiagnostics to be useful globally. Philip Felgner
discussed the use of microarray chip analysis to profile
immunity to infectious diseases. His research demon-
strates the usefulness of the technology to differentiate
immune states during infection. His goal is to develop
multi-variant microarray chips that contain several anti-
gens. Mario Roederer discussed the application of many
of his team’st e c h n i q u e sf o rH I V / S I Vv a c c i n ed e v e l o p -
ment to TB, particularly with flow cytometry’s ability to
measure immune responses at the T cell subset level.
[17] Abraham Lee presented novel microfluidic technol-
ogies that could be of great value for use in TB sero-
diagnosis or as platforms for cell and biomolecular
assays. [18] These technologies have properties that may
make them globally useful. They include low costs, pre-
cision, speed, and integration capabilities to assess mul-
tiple parameters per sample. [18] Lastly, Adrian Ozinsky
discussed the strengths and weaknesses of an application
of microfluidic tools utilizing parallel single cell assays
for TB diagnostics. While the application shows
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further define correlates of immunity and identify rele-
vant cells for measurement.
Research recommendations that emerged from
the conference
Research priorities
○ Diagnostic tools that differentiate latent M. tuber-
culosis infection from acute infection
○ Diagnostic tools that predict durable cure during
therapy and risk of relapse after therapy
○ Rapid, point of care identification of drug-resistant
TB
○ Prognostic tools to predict risk of reactivation or
progress to disease
○ Biomarkers predicting vaccine efficacy/ correlates of
protection
Areas for innovation and partnerships and cooperation
○ Leverage existing and planned clinical trials to test
potential biomarkers of disease and protection
○ Leverage new screening methodologies developed
over the past five years for genetic screens of mam-
malian cells
○ Learn from HIV vaccine development
○ Leverage technology such as microfluidics to
improve field diagnostic capabilities
○ Establish systems biologyp a r t n e r s h i p sw i t ha n
emphasis on metabolomics to identify novel
biomarkers
Conclusions
The recommendations above highlight issues that are
critical for research required to provide new tools for
TB diagnosis. The conference also acknowledged that
“turning research into tools” requires acknowledging
and correcting the limited success (or even outright fail-
ure) experienced with the deployment of technologies to
the field. Recent advances in TB diagnosis have pro-
duced tools that were not designed with pricing or per-
formance characteristics suitable for developing
countries. In addition, we need to recognize that market
forces have typically failed to deliver products that are
primarily needed for poor patients in resource-limited
countries; we need to develop pricing mechanisms or
supply strategies to address this. Moreover, the experi-
ence of HIV and malaria, two global diseases for which
cheap, simple, point-of-care tests are available, has
revealed the many weaknesses of the developing coun-
tries’ healthcare systems in management, financial and
human resources, laboratory capacity, and quality assur-
ance. Thus, public-private partnerships need to be
supported to move forward technology in areas where
private initiatives have not emerged (for example, simple
point-of-care diagnostics) and existing diagnostic capa-
city needs to be identified and strengthened.
To carry out research, development, and deployment
of new diagnostics, additional financial resources need
to be identified. The Global Plan to Stop TB 2006–2015
estimated that at least 516 million USD are needed to
strengthen TB diagnostics, yet TB diagnostics develop-
ment received only a tenth of that, according to the
2009 Treatment Action Group and Stop TB Partnership
reports [19]. While expanded funding might seem
unrealistic at a time of financial stress, it should be con-
sidered that TB prevention would be many times
cheaper than the current – unsuccessful – strategy of
treating the disease as it is found. Consequently, failure
to invest in TB control now will cost us dearly in the
future. Many public-private initiatives are currently
working in the right direction. The Global Laboratory
Initiative is leading plans for a large expansion of
laboratory services for TB, with partners such as UNI-
TAID and PEPFAR providing tens of millions of dollars
in funding for a program called EXPAND-TB that will
supply rapid MDR-TB diagnostics to 27 high-burden
countries [20]. A “TB Research Movement” has been
conceived to accelerate progress, the goal of which is to
stimulate investments, support efforts, accelerate imple-
mentation, and expand the existing portfolio across the
research continuum to ensure development of those
tools that will be conducive to global elimination of TB
by 2050 [2]. Its objectives are to provide leadership and
advocacy that will mobilize increased resources in sup-
port of a coherent and comprehensive global TB
research agenda and to provide a forum for funders and
implementers of TB research to coordinate plans and
actions, with the result of ensuring that research needs
are addressed, opportunities prioritized, and gaps filled.
[2] Finally, emerging economies such as Brazil, Russia,
India, and China are taking action to increase their
investments in tuberculosis, realizing that (i) they
account for a large proportion of the global tuberculosis
burden, and (ii) locally-manufactured, low-cost tubercu-
losis diagnostics are viable products for their emerging
pharmaceutical industries.
The “Immunodiagnosis of Tuberculosis: New Questions,
New Tools” conference successfully fostered interactions
between basic scientists and clinical investigators,
research and implementation communities, and acade-
mia and industry. It also included participation of gov-
ernment agencies, TB research and development
partnerships, intergovernmental organizations, and fund-
ing agencies promoting research and policy making in
global health. Furthermore, the participation of a diverse
audience from a global arena made it possible to convey
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from worldwide communities. Similar future initiatives
are expected to greatly contribute to attracting research-
ers in academia and industry to TB research, to fostering
communication between research and implementation
communities, and to promoting formation of intergo-
vernmental working groups to tackle neglected areas that
are critical for TB control.
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